ArticleNeuro-oncology2022

Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.

Anne Marie Barrette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.